Xen­cor, Ve­rastem ink new deals; Scynex­is' lead drug scores again

→ Xen­cor has inked a deal with Gilead Sci­ences. Gilead will have ac­cess to Xen­cor’s Xtend ex­tend­ed half-life and Cy­to­tox­ic XmAb Fc tech­nolo­gies for de­vel­op­ing and com­mer­cial­iz­ing GS-9722 — cur­rent­ly in Phase I clin­i­cal de­vel­op­ment — and up to three ad­di­tion­al an­ti-HIV an­ti­bod­ies.

→ Ve­rastem On­col­o­gy has part­nered up with Chugai Phar­ma­ceu­ti­cals to ob­tain world­wide de­vel­op­ment and com­mer­cial­iza­tion rights to Chugai’s RAF/MEK in­hibitor CH5126766 (CKI27) — cur­rent­ly un­der de­vel­op­ment for the treat­ment of KRAS mu­tant sol­id tu­mors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER